Current Drug Therapy
Title: Editorial [ Risk Benefit: Who is Responsible? ]
Volume: 2 Issue: 1
Author(s): Joachim F. Wernicke
Affiliation:
Export Options
About this article
Cite this article as:
Wernicke F. Joachim, Editorial [ Risk Benefit: Who is Responsible? ], Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422356
DOI https://dx.doi.org/10.2174/157488507779422356 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers